利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

4 条记录 (耗时 0.017 秒)

    NOVEL EP4 AGONIST
    3.
    发明公开
    NOVEL EP4 AGONIST 有权
    NEUER EP4-AGONIST

    公开(公告)号：EP2545917A1

    公开(公告)日：2013-01-16

    申请号：EP11753372.9

    申请日：2011-03-08

    申请人： Kaken Pharmaceutical Co., Ltd. ,  Asahi Glass Company, Limited

    发明人： MURATA, Takahiko ,  AMAKAWA, Masahiro ,  TERADAIRA, Shin ,  MATSUMURA, Yasushi ,  KONISHI, Katsuhiko

    IPC分类号： A61K31/41 ,  A61P1/02 ,  A61P1/04 ,  A61P1/16 ,  A61P7/00 ,  A61P9/00 ,  A61P9/10 ,  A61P11/00 ,  A61P11/06

    CPC分类号： C07D405/06 ,  C07F9/4006 ,  C07F9/6524

    摘要： Provided are a compound which is superior in metabolic stability, and selectively binds to an EP4 receptor, and a medicament containing same. It has been found that a compound represented by the formula (1):

    wherein R 1 and R 2 are each independently a hydrogen atom or a straight chain alkyl group having a carbon number of 1 - 3, R 3 is a hydrogen atom, an alkyl group having a carbon number of 1 - 4, an alkoxyalkyl group, an aryl group, a halogen atom or a haloalkyl group, or a pharmaceutically acceptable salt thereof, has, unlike known PGI 2 analogs, a selective EP4 agonist action, and therefore, a medicament containing the compound is useful for the prophylaxis and/or treatment of immune diseases, cardiovascular diseases, cardiac diseases, respiratory diseases, ophthalmic diseases, renal diseases, hepatic diseases, bone diseases, diseases of the digestive tract, neurological diseases, skin diseases and the like.

    摘要翻译： 提供了代谢稳定性优异且选择性地结合EP4受体的化合物和含有它的药物。 已经发现，由式（1）表示的化合物：其中R 1和R 2各自独立地为氢原子或碳数为1-3的直链烷基，R 3为氢原子， 具有1-4个碳原子数的烷基，烷氧基烷基，芳基，卤原子或卤代烷基或其药学上可接受的盐，与已知的PGI 2类似物不同，具有选择性EP4激动剂作用，因此 含有该化合物的药物可用于预防和/或治疗免疫疾病，心血管疾病，心脏病，呼吸系统疾病，眼科疾病，肾脏疾病，肝脏疾病，骨病，消化道疾病，神经系统疾病，皮肤 疾病等。

    NOVEL PROSTAGLANDIN I<SB>2</SB>DERIVATIVE
    4.
    发明公开
    NOVEL PROSTAGLANDIN I2DERIVATIVE 有权
    需要PROSTAGLANDIN-I2-DERIVAT

    公开(公告)号：EP2343292A1

    公开(公告)日：2011-07-13

    申请号：EP09813071.9

    申请日：2009-09-08

    申请人： Asahi Glass Company Limited ,  Kaken Pharmaceutical Co., Ltd.

    发明人： MURATA, Takahiko ,  AMAKAWA, Masahiro ,  TERADAIRA, Shin ,  MATSUMURA, Yasushi ,  KONISHI, Katsuhiko

    IPC分类号： C07D405/06 ,  A61K31/5585 ,  A61P1/00 ,  A61P1/04

    CPC分类号： C07D405/06 ,  A61K31/41

    摘要： Disclosed is a novel prostaglandin I 2 derivative which is different from known PGI 2 analogs, or a pharmaceutically acceptable salt thereof. More specifically disclosed is a 7,7-difluoro-PGI 2 derivative (formula (1)), particularly wherein R 1 and R 2 are each independently a hydrogen atom or a straight chain alkyl group having a carbon number of 1 - 3, and R 3 is a hydrogen atom, an alkyl group having a carbon number of 1 - 4, an alkoxyalkyl group, an aryl group, a halogen atom or a haloalkyl group.

    摘要翻译： 公开了与已知PGI 2类似物不同的新型前列腺素I 2衍生物或其药学上可接受的盐。 更具体地公开了7,7-二氟-PGI 2衍生物（式（1）），特别是其中R 1和R 2各自独立地为氢原子或碳数为1〜3的直链烷基，以及 R 3为氢原子，碳数为1〜4的烷基，烷氧基烷基，芳基，卤素原子或卤代烷基。